"Hippocrates said “all diseases begin in the gut”. At Genentech, my team addresses this statement by unraveling the vastly complex network of the human gut microbiome in dysbiosis and aims to develop new therapeutics to combat microbially associated diseases."
Prior to joining Genentech in 2020, I was a Principal Investigator and Associate Professor at Scripps Research in the Department of Molecular Medicine. I was attracted to Genentech’s unparalleled resources, including access to a network of world-renown scientific experts and innovative technologies that directly impact human health and disease. At Genentech, my primary focus is on the development and application of cutting-edge chemical biological approaches to discover, validate, and regulate protein functions that drive dysbiosis between humans and their respective microbiomes.
My main goal as a Genentech postdoc mentor is to provide a collaborative, inclusive atmosphere and to foster creative independent thinking to resolve important problems in human health. Team members are familiarized with the most pertinent and useful tools in chemistry, biochemistry, biophysics, immunology, and cell biology, often through collaborations with laboratories that complement our chemical biology skills. This exposure is essential to training and maturation into a well-rounded scientist. I advise lab members to approach scientific problems creatively and not be afraid to tackle their research problems using help from experts and incorporate techniques and skills outside their comfort zone. I firmly believe studying important problems in science and human health require researchers to embrace different scientific disciplines and employ a variety of experimental techniques. This philosophy is exemplified by Genentech researchers as evidenced by the cutting-edge research performed at the interface of chemistry and biology.
J. Proteome Res. 16, 1014-1026.
My lab’s research focuses on the development and application of chemical probes to understand the roles that commensal microbiome bacterial proteins play in human health and disease, and to apply this knowledge towards the development of innovative antimicrobial chemical and biological therapies. Our group designs and applies general and specific small-molecule irreversible probes in combination with mass spectrometry proteomics to survey for conserved functionalities across microbiomes as well as identify aberrant protein functions in disease. Ultimately, the specific regulation of our identified disease-associated enzymes by chemical and/or biological interventions will provide critical insights into the influence target proteins have in disease phenotypes.
Proc. Nat. Acad. Sci. USA. 359, 202006893.
J. Am. Chem. Soc. 142, 10899–10904.
Cell Chem. Biol. 25, 301-308.